Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 10, 1996, Pages 2426-2427

  Shah, L M ^a   Meyer, S C C ^a   Cynamon, M H ^a,b  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; FOLIC ACID ANTAGONIST; PYRIMETHAMINE; SULFONE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL;

EID: 0029797530     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.10.2426     Document Type: Article

References (8)

1. Edstein, M. D., J. R. Veenendaal, and K. H. Rieckman. 1990. Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. Pharmacology 36:169-176.
2. Lane, C. H., B. E. Laughon, J. Falloon, J. A. Kovacs, R. T. Davey, Jr., M. A. Polis, and H. Masur. 1994. Recent advances in the management of AIDS-related opportunistic infections. Ann. Intern. Med. 120:945-955.
3. Leport, C., G. Chêne, P. Mortal, B. J. Luft, F. Rousseau, S. Pueyo, R. Hafner, J. Miro, J. Aubertin, R. Salamon, J.-L. Vildé, and ANRS 005-ACTG 154 Group Members. 1996. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. J. Infect. Dis. 173:91-97.
4. Opravil, M., B. Hirschel, A. Lazzarin, A. Heald, M. Pechère, S. Ruttimann, A. Iten, J. von Overbeck, D. Oertle, G. Praz, D. A. Vuitton, F. Mainini, and R. Luthy. 1995. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystia carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 20:531-541.
5. Opravil, M., B. Joos, and R. Luthy. 1994. Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob. Agents Chemother. 38:1197-1199.
6. Opravil, M., M. Pechère, A. Lazzarin, A. Heald, S. Ruttimann, A. Iten, H. Furrer, D. Oertle, G. Praz, D. A. Vuitton, B. Hirschel, and R. Luthy. 1995. Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the immunodeficiency virus. Clin. Infect. Dis. 20:244-249.
7. Shah, L. M., M. D. DeStefano, and M. H. Cynamon. 1996. Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex, abstr. U-67, p. 112. In Abstracts of the 96th General Meeting of the American Society for Microbiology 1996. American Society for Microbiology, Washington, D.C.
8. Webster, L. T., Jr. 1993. Drugs used in the chemotherapy of protozoal infections. In A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor (ed.), Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill Book Co., New York.